Cargando…

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress

The compound APR-246 (PRIMA-1(MET)) is a known reactivator of (mutant) p53 and inducer of oxidative stress which can sensitize cancer cells to platinum-based chemotherapeutics. However, the effect of a hypoxic tumor environment has been largely overlooked in this interaction. This study focusses on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deben, Christophe, Deschoolmeester, Vanessa, De Waele, Jorrit, Jacobs, Julie, Van den Bossche, Jolien, Wouters, An, Peeters, Marc, Rolfo, Christian, Smits, Evelien, Lardon, Filip, Pauwels, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923381/ https://www.ncbi.nlm.nih.gov/pubmed/29690507 http://dx.doi.org/10.3390/cancers10040126

Ejemplares similares

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients
por: Deben, Christophe, et al.
Publicado: (2017)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
por: De Waele, Jorrit, et al.
Publicado: (2021)

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
por: Van Loenhout, Jinthe, et al.
Publicado: (2021)

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
por: Boeckx, Carolien, et al.
Publicado: (2015)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
por: Verhoeven, Yannick, et al.
Publicado: (2021)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
por: Baysal, Hasan, et al.
Publicado: (2021)

The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein
por: Wouters, An, et al.
Publicado: (2014)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
por: Limame, Ridha, et al.
Publicado: (2012)

Cellular senescence in cancer: clinical detection and prognostic implications
por: Domen, Andreas, et al.
Publicado: (2022)

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
por: Deben, Christophe, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
por: Domen, Andreas, et al.
Publicado: (2021)

Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
por: Baay, Marc, et al.
Publicado: (2011)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
por: Zaryouh, Hannah, et al.
Publicado: (2021)

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
por: Freire Boullosa, Laurie, et al.
Publicado: (2021)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
por: Boeckx, Carolien, et al.
Publicado: (2014)

Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol
por: Sorber, Laure, et al.
Publicado: (2019)

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects
por: Van Loenhout, Jinthe, et al.
Publicado: (2020)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
por: Flieswasser, Tal, et al.
Publicado: (2023)

Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients
por: Berghmans, Eline, et al.
Publicado: (2020)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_01egm22uvbjof6kgpc37qb4s8v